Skip to content

Effect of aerobic dance on natural killer cells and leptin levels in breast cancer patients undergoing adjuvant hormone therapy with different BMI

Effect of aerobic dance on natural killer cells subsets and leptin levels in breast cancer patients undergoing adjuvant hormone therapy with different BMIs: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202512842728378
Enrollment
80
Registered
2025-12-23
Start date
2024-03-12
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Nutritional, Metabolic, Endocrine

Interventions

Aerobic Danse Training Program
Usual care. No structured exercise

Sponsors

Jihen Khalfoun
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: - women aged between 18 to 65 years, - RH+ breast cancer (ER±/PR±), Her2- , - ECOG performance status 0–1; medical clearance for exercise - no known history of chronic respiratory, cardiac, or neuromuscular disease, - who had been diagnosed with non-metastatic (M0) breast cancer. -All had undergone initial surgery, completed chemotherapy and radiotherapy, and were receiving adjuvant hormone therapy (0 to 5 years) (aromatase inhibitor "Letrozole"). - Patients had to be able to participate in a moderate physical activity program, as assessed by a healthcare professional. - They were recruited from among women living in Greater Tunis - Participants also had to be available and committed to following the entire training program planned for the study.

Exclusion criteria

Exclusion criteria: - prior enrollment in a structured exercise program before the start of the study - current smoking - simultaneous participation in alternative or complementary treatments not supervised by the hospital's oncology or rehabilitation services - history or diagnosis of another cancer. - women under the age of 18 and over the age of 65

Design outcomes

Primary

MeasureTime frame
- Variation in NK cell subsets CD3?CD16?CD56? (cytotoxic NK cells), CD3?CD16?CD56? (regulatory NK cells) , NK cell degranulation by CD107a expression , Leptin receptor expression on NK cells by CD295 (Ob-R) marker for each group: normal weight, overweight patients, patients with obesity class 1, 2, and 3

Secondary

MeasureTime frame
Anthropometric measurements: weight, height, fat mass, muscle mass, BMI, metabolic protein mass, basal metabolic rate, bone mineral density, intracellular water, extracellular water, fat/lean cardiac risk Questionnaire: quality of life and anxiety and depression scale for each group: normal weight, overweight patients, patients with obesity class 1, 2, and 3

Countries

Tunisia

Contacts

Public ContactHaifa Rachdi

Associate Professor in the Medical Oncology Department at Abderrahmane Mami Hospital. Ministry of Health

haifa.rachdi@yahoo.fr+21658862984

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026